Brief: Allarity Therapeutics-On Feb 8 Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard Transfer Of Listing From Nasdaq
10/02/2023 22:08
Allarity Therapeutics Inc ALLR.O :
* ALLARITY THERAPEUTICS-ON FEB 8 RECEIVED NOTICE OF
DELISTING OR
FAILURE TO SATISFY CONTINUED LISTING RULE OR STANDARD; TRANSFER
OF LISTING FROM NASDAQ
Source text for Eikon: ID:
Further company coverage: ALLR.O
Recent news on Allarity Therapeutics
See all newsBrief: Allarity Therapeutics Announces Strategic Capital Allocation For Filing Of Spac Registration Statement
Allarity Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Allarity Therapeutics Q2 loss narrows as expenses fall
Allarity Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Allarity Therapeutics Announces The Grant Of Essential U.S. Patent For Its Stenoparib Drp® Companion Diagnostic